Prognostic value of choline and creatine in WHO grade II gliomas

IntroductionThe purpose of this study was to evaluate whether proton magnetic resonance spectroscopy (1H-MRS) predicts survival time, tumor progression, and malignant transformation in patients with WHO grade II gliomas.Materials and methods1H-MRS and MR imaging (MRI) were performed before surgery in 45 patients with histologically proven WHO grade II gliomas. Metabolite concentrations of choline-containing compounds (Cho) and creatine/phosphocreatine (tCr) were normalized to contralateral brain tissue. Spectroscopic data as well as the extent of tumor resection, contrast enhancement, size and histopatholocical type of the tumor, age, sex, and first neurological symptoms of the patients were analyzed for survival, tumor progression, and malignant transformation for a follow-up period of 1 to 5 years.ResultsThe normalized tCr of WHO grade II gliomas was a significant predictor for tumor progression (p = 0.011) and for malignant tumor transformation (p = 0.016). Further, contrast enhancement of the tumor (p = 0.014) at the time of diagnosis was significant for malignant tumor transformation and extent of tumor resection for the tumor progression (p = 0.007). All other parameters failed to predict any of the three endpoints.ConclusionNormalized values of tCr in WHO grade II gliomas may have prognostic implications for this group of gliomas. As a rule of the thumb, low-grade gliomas with decreased tCr (relative tCr values below 1.0) may show longer progression-free times and later malignant transformation than low-grade gliomas with regular or increased tCr values.

[1]  A. Chiò,et al.  Prognostic factors in well-differentiated cerebral astrocytomas in the adult. , 1989, Neurosurgery.

[2]  J. Crowley,et al.  A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. , 1993, Journal of neurosurgery.

[3]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[4]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[5]  J. Frahm,et al.  Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. , 1993, Radiology.

[6]  R. Gillies,et al.  In Vitro and in Vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells , 1994, Magnetic resonance in medicine.

[7]  Hidehiko Kajiwara,et al.  Proton Magnetic Resonance Spectroscopy of Brain TumorsAn In Vitro Study , 1994 .

[8]  M. Berger,et al.  The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas , 1994, Cancer.

[9]  Y. Kinoshita,et al.  Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. , 1994, Neurosurgery.

[10]  D J Jenden,et al.  In vivo 1H MRS choline: correlation with in vitro chemistry/histology. , 1996, Life sciences.

[11]  M. Scerrati,et al.  Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[12]  A. Karim,et al.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. , 1996, International journal of radiation oncology, biology, physics.

[13]  K. Hara,et al.  Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. , 1996, AJNR. American journal of neuroradiology.

[14]  K. Skullerud,et al.  Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. , 1997 .

[16]  D. Leibfritz,et al.  Metabolism of Glycine in Primary Astroglial Cells: Synthesis of Creatine, Serine, and Glutathione , 1998, Journal of neurochemistry.

[17]  C. Avezaat,et al.  Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery , 1998, Journal of neurology, neurosurgery, and psychiatry.

[18]  M. Leach,et al.  Signal modulation in 1H magnetic resonance spectroscopy using contrast agents: Proton relaxivities of choline, creatine, and N‐acetylaspartate , 1999, Magnetic resonance in medicine.

[19]  H. Shimizu,et al.  Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. , 2000, AJNR. American journal of neuroradiology.

[20]  H. Lanfermann,et al.  Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions , 2002, Neuroradiology.

[21]  J. Nelson,et al.  Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. , 2001, Cancer research.

[22]  G B Matson,et al.  Short echo time multislice proton magnetic resonance spectroscopic imaging in human brain: metabolite distributions and reliability. , 2001, Magnetic resonance imaging.

[23]  Philippe Cornu,et al.  Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. , 2002, International journal of radiation oncology, biology, physics.

[24]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Ying Lu,et al.  Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients , 2002, Journal of magnetic resonance imaging : JMRI.

[26]  Heinrich Lanfermann,et al.  Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors , 2002, NMR in biomedicine.

[27]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Arnold,et al.  Proton Magnetic Resonance Spectroscopic Imaging Can Predict Length of Survival in Patients with Supratentorial Gliomas , 2003, Neurosurgery.

[29]  Damien Galanaud,et al.  Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. , 2003, Journal of neurosurgery.

[30]  Oded Gonen,et al.  Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. , 2003, Magnetic resonance imaging.

[31]  N. Probst-Hensch,et al.  Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas , 2004, Acta Neuropathologica.

[32]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[33]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[34]  B. Scheithauer,et al.  Supratentorial gliomas: a comparative study by grade and histologic type , 1997, Journal of Neuro-Oncology.

[35]  M. Piérart,et al.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial , 2005, The Lancet.

[36]  M. Taphoorn,et al.  Proton MRS imaging in the follow-up of patients with suspected low-grade gliomas , 2005, Neuroradiology.

[37]  T. Ryken,et al.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? , 2005, AJNR. American journal of neuroradiology.

[38]  Tommaso Scarabino,et al.  Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy , 2006, Neuroradiology.

[39]  F. Gilles,et al.  Quantitative short echo time 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. , 2006, AJNR. American journal of neuroradiology.

[40]  Quantitative analysis of whole‐tumor Gd enhancement histograms predicts malignant transformation in low‐grade gliomas , 2007, Journal of magnetic resonance imaging : JMRI.

[41]  Y. Liu,et al.  Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2 , 2007, Neuroradiology.

[42]  H. Lanfermann,et al.  Myo‐Inositol: a marker of reactive astrogliosis in glial tumors? , 2008, NMR in biomedicine.

[43]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .